[
  {
    "ts": "2026-02-23T09:09:00+00:00",
    "headline": "Merck RSV And KEYTRUDA Updates Refocus Attention On Valuation And Growth",
    "summary": "Merck (NYSE:MRK) reported positive Phase 3 SMART trial results for ENFLONSIA, showing protection against RSV in high risk infants during a second RSV season. The findings expand the potential use of ENFLONSIA beyond current approvals for RSV prevention in young children. The FDA also approved new formulations and indications for KEYTRUDA, including the first subcutaneous option and new uses for KEYTRUDA and KEYTRUDA QLEX in certain hard to treat cancers. For you as an investor, this news...",
    "url": "https://finance.yahoo.com/news/merck-rsv-keytruda-updates-refocus-090900730.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "3c7651a1-95a3-332a-b998-5a03aae2a9eb",
      "content": {
        "id": "3c7651a1-95a3-332a-b998-5a03aae2a9eb",
        "contentType": "STORY",
        "title": "Merck RSV And KEYTRUDA Updates Refocus Attention On Valuation And Growth",
        "description": "",
        "summary": "Merck (NYSE:MRK) reported positive Phase 3 SMART trial results for ENFLONSIA, showing protection against RSV in high risk infants during a second RSV season. The findings expand the potential use of ENFLONSIA beyond current approvals for RSV prevention in young children. The FDA also approved new formulations and indications for KEYTRUDA, including the first subcutaneous option and new uses for KEYTRUDA and KEYTRUDA QLEX in certain hard to treat cancers. For you as an investor, this news...",
        "pubDate": "2026-02-23T09:09:00Z",
        "displayTime": "2026-02-23T09:09:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kA84g.s9IO2ClCgTX6BCgg--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DmY770n7xz5DXLM6ZHLmxA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/d7ea461ebd942c5c61a3f68254dc45cf.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-rsv-keytruda-updates-refocus-090900730.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-rsv-keytruda-updates-refocus-090900730.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T11:00:00+00:00",
    "headline": "Merck Creates Separate Cancer Business as Sales Pressure Looms",
    "summary": "The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss.",
    "url": "https://www.wsj.com/health/pharma/merck-creates-separate-cancer-business-as-sales-pressure-looms-2d6b1b65?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "1294a80f-f8cf-3e61-b2a8-5ff24999fc89",
      "content": {
        "id": "1294a80f-f8cf-3e61-b2a8-5ff24999fc89",
        "contentType": "STORY",
        "title": "Merck Creates Separate Cancer Business as Sales Pressure Looms",
        "description": "",
        "summary": "The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss.",
        "pubDate": "2026-02-23T11:00:00Z",
        "displayTime": "2026-02-23T11:00:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/1294a80f-f8cf-3e61-b2a8-5ff24999fc89/merck-creates-separate-cancer.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/22fcebf0a9c49f430c5039a9ef2297ad",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gj_W3CKizDFlEqCnTReZOw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/22fcebf0a9c49f430c5039a9ef2297ad.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/O_2Jg27ecAKYizf5qPXVDg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/22fcebf0a9c49f430c5039a9ef2297ad.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/health/pharma/merck-creates-separate-cancer-business-as-sales-pressure-looms-2d6b1b65?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T11:45:00+00:00",
    "headline": "Merck Evolves Human Health Operating Structure to Support Portfolio Execution",
    "summary": "RAHWAY, N.J., February 23, 2026--Merck Evolves Human Health Operating Structure to Support Portfolio Execution",
    "url": "https://finance.yahoo.com/news/merck-evolves-human-health-operating-114500732.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "862311bc-1acf-3a08-932d-4f8a884908ec",
      "content": {
        "id": "862311bc-1acf-3a08-932d-4f8a884908ec",
        "contentType": "STORY",
        "title": "Merck Evolves Human Health Operating Structure to Support Portfolio Execution",
        "description": "",
        "summary": "RAHWAY, N.J., February 23, 2026--Merck Evolves Human Health Operating Structure to Support Portfolio Execution",
        "pubDate": "2026-02-23T11:45:00Z",
        "displayTime": "2026-02-23T11:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/d2635a4dae6648e9ac9e49a81f3e7d1a",
          "originalWidth": 480,
          "originalHeight": 217,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/brDlgYBCeDoZPtNGNwLAtg--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/d2635a4dae6648e9ac9e49a81f3e7d1a.cf.webp",
              "width": 480,
              "height": 217,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/CQg0y8L1NoqejHlq3AwJFw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/d2635a4dae6648e9ac9e49a81f3e7d1a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-evolves-human-health-operating-114500732.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-evolves-human-health-operating-114500732.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T11:40:29+00:00",
    "headline": "Merck to create separate cancer business to offset Keytruda patent loss, WSJ reports",
    "summary": "Feb 23 () - Merck is splitting its human-health business into two ‌divisions to offset pressures ‌related to the loss of patent for its ​top-selling drug Keytruda, the Wall Street Journal reported on Monday. One division will house its cancer drugs, including ‌Keytruda, while ⁠the other will sell its non-cancer products, the report ⁠said.",
    "url": "https://finance.yahoo.com/news/merck-create-separate-cancer-business-112250919.html",
    "source": "Reuters",
    "provider": "yfinance",
    "raw": {
      "id": "31473e69-3265-3725-b484-ff1ee5e5f35c",
      "content": {
        "id": "31473e69-3265-3725-b484-ff1ee5e5f35c",
        "contentType": "STORY",
        "title": "Merck to create separate cancer business to offset Keytruda patent loss, WSJ reports",
        "description": "",
        "summary": "Feb 23 () - Merck is splitting its human-health business into two ‌divisions to offset pressures ‌related to the loss of patent for its ​top-selling drug Keytruda, the Wall Street Journal reported on Monday. One division will house its cancer drugs, including ‌Keytruda, while ⁠the other will sell its non-cancer products, the report ⁠said.",
        "pubDate": "2026-02-23T11:40:29Z",
        "displayTime": "2026-02-23T11:40:29Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/reuters.com/c184d10982098f00220e92d0693de11f",
          "originalWidth": 800,
          "originalHeight": 533,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OZli0WMw3h5V8hOA_ZD47A--~B/aD01MzM7dz04MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/c184d10982098f00220e92d0693de11f.cf.webp",
              "width": 800,
              "height": 533,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/d6AJJeCNLAeEoligiOeiZQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/reuters.com/c184d10982098f00220e92d0693de11f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters",
          "url": "https://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-create-separate-cancer-business-112250919.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-create-separate-cancer-business-112250919.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-23T11:32:02+00:00",
    "headline": "Stocks to Watch Monday: Domino's Pizza, Eli Lilly, Merck, Gilead",
    "summary": "↗️ Merck (MRK): The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss. One will house its cancer drugs, including blockbuster Keytruda. Shares rose roughly 1.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-tariffs-02-23-2026/card/stocks-to-watch-monday-domino-s-pizza-dominion-energy-american-airlines-RT1RccoqGTzQdkbqaSL7?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "cb781f9d-b9a5-3f5a-bfb4-b439b3b47382",
      "content": {
        "id": "cb781f9d-b9a5-3f5a-bfb4-b439b3b47382",
        "contentType": "STORY",
        "title": "Stocks to Watch Monday: Domino's Pizza, Eli Lilly, Merck, Gilead",
        "description": "",
        "summary": "↗️ Merck (MRK): The drugmaker is splitting its pharmaceuticals unit to bolster product launches before a crucial patent loss. One will house its cancer drugs, including blockbuster Keytruda. Shares rose roughly 1.",
        "pubDate": "2026-02-23T11:32:02Z",
        "displayTime": "2026-02-23T11:32:02Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/cb781f9d-b9a5-3f5a-bfb4-b439b3b47382/stocks-to-watch-monday-.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KnlNOKh2C6QgkEmemrj6mg--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zhLP7itajp.wiPUq1vzKdA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/6f2132c0e52008396d8b8cc39474d877.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-tariffs-02-23-2026/card/stocks-to-watch-monday-domino-s-pizza-dominion-energy-american-airlines-RT1RccoqGTzQdkbqaSL7?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "NOVO.B"
            },
            {
              "symbol": "GILD"
            },
            {
              "symbol": "DPZ"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "ACLX"
            },
            {
              "symbol": "AAL"
            },
            {
              "symbol": "DAL"
            },
            {
              "symbol": "UAL"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]